Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALalB/c mice

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 3265-3276

  Thakkar, Arvind ^a   Chenreddy, Sushma ^a   Thio, Astrid ^a   Khamas, Wael ^a   Wang, Jeffrey ^a   Prabhu, Sunil ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Aspirin; Chitosan solid lipid nanoparticle; Curcumin; Pancreatic cancer; Sulforaphane; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; CHITOSAN; CURCUMIN; SOLID LIPID NANOPARTICLE; SULFORAPHANE; ISOTHIOCYANIC ACID DERIVATIVE; LIPID; NANOPARTICLE; SULFORAFAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BODY WEIGHT; BRAIN; CONTROLLED STUDY; DRUG RELEASE; ENCAPSULATION; ENCAPSULATION EFFICIENCY; FEMALE; HEART; HEMATOLOGY; HISTOPATHOLOGY; IN VIVO STUDY; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; PANCREAS; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYDISPERSITY INDEX; SURVIVAL; TOXICITY; TOXICITY TESTING; ZETA POTENTIAL; ANIMAL; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; STATIC ELECTRICITY;

ADMINISTRATION, ORAL; ANIMALS; ASPIRIN; BODY WEIGHT; CHITOSAN; CURCUMIN; DRUG LIBERATION; FEMALE; ISOTHIOCYANATES; LIPIDS; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; STATIC ELECTRICITY; TOXICITY TESTS;

EID: 84982272488     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S106736     Document Type: Article

References (50)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279(15): 1200-1205.
2. Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993; 27(7-8): 832-840.
3. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006; 6(7): 546-558.
4. Wynn RL. Erythromycin and ketoconazole (Nizoral) associated with terfenadine (Seldane)-induced ventricular arrhythmias. Gen Dent. 1993; 41(1): 27-29.
5. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996; 335(4): 290-291.
6. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet. 2000; 39(1): 49-75.
7. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions. Am J Gastroenterol. 2001; 96(6): 1698-1703.
8. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003; 289(13): 1652-1658.
9. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998; 64(1): 123-128.
10. Brown BA, Wallace RJ Jr, Griffith DE, Warden R. Clarithromycin-associated digoxin toxicity in the elderly. Clin Infect Dis. 1997; 24(1): 92-93.
11. Guerriero SE, Ehrenpreis E, Gallagher KL. Two cases of clarithromycin-induced digoxin toxicity. Pharmacotherapy. 1997; 17(5): 1035-1037.
12. Grandhi BK, Thakkar A, Wang J, Prabhu S. A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res. 2013; 6(10): 1015-1025.
13. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release. 2003; 93(2): 151-160.
14. Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res. 2015; 32(2): 389-402.
15. Luo Y, Teng Z, Li Y, Wang Q. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr Polym. 2015; 122: 221-229.
16. Arya G, Vandana M, Acharya S, Sahoo SK. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine. 2011; 7(6): 859-870.
17. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999; 5(4): 387-391.
18. Maezaki Y, Tsuji K, Nakagawa Y, et al. Hypocholesterolemic effect of chitosan in adult males. Biosci Biotechnol Biochem. 1993; 57(9): 1439-1444.
19. Chen MC, Mi FL, Liao ZX, et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev. 2013; 65(6): 865-879.
20. Yuan H, Jiang SP, Du YZ, Miao J, Zhang XG, Hu FQ. Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles. Colloids Surf B Biointerfaces. 2009; 70(2): 248-253.
21. Sakloetsakun D, Perera G, Hombach J, Millotti G, Bernkop-Schnürch A. The impact of vehicles on the mucoadhesive properties of orally administrated nanoparticles: a case study with chitosan-4-thiobutylamidine conjugate. AAPS PharmSciTech. 2010; 11(3): 1185-1192.
22. Fonte P, Andrade F, Araújo F, Andrade C, Neves J, Sarmento B. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol. 2012; 508: 295-314.
23. Cole ET, Scott RA, Connor AL, et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm. 2002; 231(1): 83-95.
24. Sutaria D, Grandhi BK, Thakkar A, Wang J, Prabhu S. Chemoprevention of pancreatic cancer using solid lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen. Int J Oncol. 2012; 41(6): 2260-2268.
25. Thakkar A, Sutaria D, Grandhi BK, Wang J, Prabhu S. The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer. Oncol Rep. 2013; 29(4): 1671-1677.
26. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849-1860.
27. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med. 2006; 30(1): 74-77.
28. Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf. 2011; 10(1): 45-54.
29. Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012; 156(1): 69-75.
30. Sikora E, Scapagnini G, Barbagallo M. Curcumin, inflammation, ageing and age-related diseases. Immun Ageing. 2010; 7(1): 1.
31. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21(4B): 2895-2900.
32. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008; 14(14): 4491-4499.
33. Noh JR, Kim YH, Hwang JH, et al. Sulforaphane protects against acetaminophen-induced hepatotoxicity. Food Chem Toxicol. 2015; 80: 193-200.
34. Philbrook NA, Winn LM. Sub-chronic sulforaphane exposure in CD-1 pregnant mice enhances maternal NADPH quinone oxidoreductase 1 (NQO1) activity and mRNA expression of NQO1, glutathione S-transferase, and glutamate-cysteine ligase: potential implications for fetal protection against toxicant exposure. Reprod Toxicol. 2014; 43: 30-37.
35. Jiao Z, Zhang Q, Chang J, et al. A protective role of sulforaphane on alveolar epithelial cells exposed to cigarette smoke extract. Exp Lung Res. 2013; 39(9): 379-386.
36. Sze A, Erickson D, Ren L, Li D. Zeta-potential measurement using the Smoluchowski equation and the slope of the current-time relationship in electroosmotic flow. J Colloid Interface Sci. 2003; 261(2): 402-410.
37. OECD. Test No 407: Repeated Dose 28-day Oral Toxicity Study in Rodents. OECD Publishing. Paris.
38. OECD. Test No 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents. OECD Publishing. Paris.
39. de Castro MD, Izquierdo A. Lyophilization: a useful approach to the automation of analytical processes? J Automat Chem. 1990; 12(6): 267-279.
40. Yen FL, Wu TH, Tzeng CW, Lin LT, Lin CC. Curcumin nanoparticles improve the physicochemical properties of curcumin and effectively enhance its antioxidant and antihepatoma activities. J Agric Food Chem. 2010; 58(12): 7376-7382.
41. Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul. 2008; 2(2): 120-135.
42. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine. 2010; 6(6): 714-729.
43. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004; 56(9): 1257-1272.
44. Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm. 2000; 196(2): 161-164.
45. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000; 46(12): 2050-2068.
46. Amacher DE. A toxicologist’s guide to biomarkers of hepatic response. Hum Exp Toxicol. 2002; 21(5): 253-262.
47. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008; 245(3): 194-205.
48. Zhang XD, Wu D, Shen X, et al. Size-dependent in vivo toxicity of PEG-coated gold nanoparticles. Int J Nanomedicine. 2011; 6: 2071-2081.
49. Miller WG, Myers GL, Ashwood ER, et al. Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med. 2005; 129(3): 297-304.
50. Rosner MH, Bolton WK. Renal function testing. Am J Kidney Dis. 2006; 47(1): 174-183.